Iveric Bio : Corporate Overview August 2022

FOR RETINAL DISEASES

August 2022

NASDAQ: ISEE

Forward looking statements

Any statements in this presentation about the Company's expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company's strategy, future operations and future expectations, plans and prospects, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

In this presentation, the Company's forward looking statements include statements about its expectations regarding availability of top-line data from and

patient retention in its second Phase 3 trial (GATHER2) of Zimura in geographic atrophy secondary to AMD, its ability to use its completed clinical trial of

Zimura for the treatment of geographic atrophy secondary to AMD (GATHER1) as a Phase 3 trial for purposes of seeking regulatory approval, its development and regulatory strategy for Zimura and its other product candidates, including additional indications, such as intermediate AMD, that the Company may pursue for the development of Zimura and IC-500, its ability to obtain the first marketing approval for the treatment of geographic atrophy and its expectations regarding the market dynamics for the treatment of GA and other commercial matters, the Company's hypotheses regarding complement inhibition and HtrA1 inhibition as potential mechanisms of action for the treatment of retinal diseases, the implementation of its business and hiring plan, expectations regarding its cash and financial resources, the timing, progress and results of clinical trials and other research and development activities, including regulatory submissions, the clinical meaningfulness of clinical trial results, the potential utility of its product candidates, estimates

regarding the number of patients affected by the diseases and indications the Company's product candidates are intended to treat and statements

regarding the potential for the Company's business development strategy.

Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's research and development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the progression and duration of the COVID-19 pandemic and responsive measures thereto and related effects on the Company's research and development programs, operations and financial position, expectations for regulatory matters, the initiation and the progress of research and development programs and clinical trials, including enrollment and retention in clinical trials, availability of data from these programs,

reliance on contract development and manufacturing organizations, contract research organizations and other third parties, establishment of

manufacturing capabilities, developments from the Company's competitors and the marketplace for the Company's products, human capital matters, need for additional financing and other factors discussed in the "Risk Factors" section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission.

Any forward-looking statements represent the Company's views only as of the date of this presentation. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.

2

Positioned to be the leader in retina

Therapeutics for Age-Related Retinal Diseases (Large Market)

• Zimura (C5 inhibitor):

• Positive data for the first of two Phase 3 trials (GATHER1)

• • 1. Statistically significant 27% reduction in GA growth over 12 months (primary endpoint achieved)
  • Completed patient enrollment for second Phase 3 trial (GATHER2) in July 2021; topline data expected in September 2022
  • Received Special Protocol Assessment (SPA) from FDA for GATHER2
  • Plan to file for NDA/MAA approvals following positive 12-month GATHER2 data
  • Commercial planning underway; potential for market leading position
  • Plan to initiate clinical development in intermediate AMD in 4Q2022 with additional lifecycle initiatives ongoing
• IC-500(HtrA1 Inhibitor): Complementary MOA adding to development stage AMD franchise

Cash Position

• Expected YE 2022 cash: $260 million - $270 million*

*Estimate as of 7/26/22

3

STRONG SENIOR TEAM WITH SIGNIFICANT OPHTHALMOLOGY EXPERIENCE

GLENN SBLENDORIO

Chief Executive Officer

PRAVIN DUGEL, MD

President

DAVID CARROLL

Chief Financial Officer

TONY GIBNEY

Chief Business & Strategy Officer

KEITH WESTBY

Chief Operating Officer

XIAO-PING DAI, PhD

Chief Technical Officer

CHRISTOPHER SIMMS

Chief Commercial Officer

EVELYN HARRISON

Chief Clinical Operations Officer

DHAVAL DESAI, PHARMD

Chief Development Officer

SNEHAL SHAH, PHARMD

Chief Regulatory and Pharmacovigilance Officer

4

Iveric Bio Pipeline

5